AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $1.43 billion. The enterprise value is $1.54 billion.
| Market Cap | 1.43B |
| Enterprise Value | 1.54B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 29.90 million shares outstanding. The number of shares has increased by 26.17% in one year.
| Current Share Class | 29.90M |
| Shares Outstanding | 29.90M |
| Shares Change (YoY) | +26.17% |
| Shares Change (QoQ) | +25.39% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 79.32% |
| Float | 20.44M |
Valuation Ratios
The trailing PE ratio is 6.85 and the forward PE ratio is 13.48.
| PE Ratio | 6.85 |
| Forward PE | 13.48 |
| PS Ratio | 13.49 |
| Forward PS | 10.96 |
| PB Ratio | 127.59 |
| P/TBV Ratio | 135.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 5.86 |
| EV / Sales | 14.48 |
| EV / EBITDA | 23.38 |
| EV / EBIT | 23.38 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.61, with a Debt / Equity ratio of 25.47.
| Current Ratio | 5.61 |
| Quick Ratio | 5.54 |
| Debt / Equity | 25.47 |
| Debt / EBITDA | 4.10 |
| Debt / FCF | n/a |
| Interest Coverage | 0.80 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 109.79% |
| Return on Capital Employed (ROCE) | 23.33% |
| Weighted Average Cost of Capital (WACC) | 9.49% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | $2.52M |
| Employee Count | 104 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -362.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.88% in the last 52 weeks. The beta is 0.45, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +35.88% |
| 50-Day Moving Average | 53.03 |
| 200-Day Moving Average | 56.41 |
| Relative Strength Index (RSI) | 45.94 |
| Average Volume (20 Days) | 584,073 |
Short Selling Information
The latest short interest is 5.24 million, so 17.52% of the outstanding shares have been sold short.
| Short Interest | 5.24M |
| Short Previous Month | 5.44M |
| Short % of Shares Out | 17.52% |
| Short % of Float | 25.62% |
| Short Ratio (days to cover) | 8.96 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $106.09 million and earned $261.99 million in profits. Earnings per share was $7.00.
| Revenue | 106.09M |
| Gross Profit | 111.42M |
| Operating Income | 65.70M |
| Pretax Income | -10.19M |
| Net Income | 261.99M |
| EBITDA | 65.71M |
| EBIT | 65.70M |
| Earnings Per Share (EPS) | $7.00 |
Balance Sheet
The company has $164.14 million in cash and $269.59 million in debt, with a net cash position of -$105.45 million or -$3.53 per share.
| Cash & Cash Equivalents | 164.14M |
| Total Debt | 269.59M |
| Net Cash | -105.45M |
| Net Cash Per Share | -$3.53 |
| Equity (Book Value) | 10.59M |
| Book Value Per Share | 0.36 |
| Working Capital | 163.07M |
Cash Flow
In the last 12 months, operating cash flow was -$105.12 million and capital expenditures -$69,000, giving a free cash flow of -$105.12 million.
| Operating Cash Flow | -105.12M |
| Capital Expenditures | -69,000 |
| Depreciation & Amortization | 18,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -105.12M |
| FCF Per Share | -$3.52 |
Margins
Gross margin is 105.03%, with operating and profit margins of 61.93% and 246.96%.
| Gross Margin | 105.03% |
| Operating Margin | 61.93% |
| Pretax Margin | -9.60% |
| Profit Margin | 246.96% |
| EBITDA Margin | 61.94% |
| EBIT Margin | 61.93% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.17% |
| Shareholder Yield | -26.17% |
| Earnings Yield | 14.60% |
| FCF Yield | -7.35% |
Analyst Forecast
The average price target for AnaptysBio is $87.25, which is 82.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $87.25 |
| Price Target Difference | 82.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 38.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of 1.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.24 |
| Piotroski F-Score | 3 |